{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:18:34Z","timestamp":1781374714925,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.saa.2018.07.040","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T17:50:28Z","timestamp":1532109028000},"page":"292-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["An experimental ninhydrin design approach for the sensitive spectrofluorimetric assay of milnacipran in human urine and plasma"],"prefix":"10.1016","volume":"205","author":[{"given":"Islam M.","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed M.","family":"Derayea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia M.","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.saa.2018.07.040_bb0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biopsych.2003.07.006","article-title":"Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity","volume":"55","author":"Vaishnavi","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.saa.2018.07.040_bb0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/WNF.0b013e3181ac155b","article-title":"Milnacipran: beyond a role of antidepressant","volume":"32","author":"Pae","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.saa.2018.07.040_bb0015","series-title":"Martindale: The Complete Drug Reference","author":"Sweetman","year":"2009"},{"key":"10.1016\/j.saa.2018.07.040_bb0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1358\/dot.2008.44.9.1256003","article-title":"Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome","volume":"44","author":"Owen","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.saa.2018.07.040_bb0025","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.14233\/ajchem.2013.13716","article-title":"Spectrophotometric determination of nor-epinephrine serotonin reuptake inhibitor (SNRI) drug Milnacipran in pure and in dosage forms","volume":"25","author":"Singhvi","year":"2013","journal-title":"Asian J. Chem."},{"key":"10.1016\/j.saa.2018.07.040_bb0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11094-016-1449-3","article-title":"Simple and sensitive colorimetric method for the determination of milnacipran in bulk and swellable matrix tablets","volume":"50","author":"Hussain","year":"2016","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.saa.2018.07.040_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jchromb.2004.03.063","article-title":"Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection","volume":"806","author":"Puozzo","year":"2004","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.saa.2018.07.040_bb0040","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/jssc.200800291","article-title":"Chiral analysis of milnacipran by a nonchiral HPLC\u2013circular dichroism: improvement of the linearity of dichroic response by temperature control","volume":"31","author":"Lecoeur-Lorin","year":"2008","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.saa.2018.07.040_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/chir.20496","article-title":"Chiral HPLC analysis of milnacipran and its FMOC-derivative on cellulose-based stationary phases","volume":"20","author":"Patti","year":"2008","journal-title":"Chirality"},{"key":"10.1016\/j.saa.2018.07.040_bb0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1365\/s10337-010-1607-9","article-title":"Determination of milnacipran in human plasma using GC\u2013MS","volume":"72","author":"U\u00e7akt\u00fcrk","year":"2010","journal-title":"Chromatographia"},{"key":"10.1016\/j.saa.2018.07.040_bb0055","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1556\/JPC.24.2011.5.9","article-title":"Stability-indicating HPTLC method for determination of milnacipran hydrochloride in pharmaceutical formulations","volume":"24","author":"Khatri","year":"2011","journal-title":"J. Planar Chromatogr.\u2013Mod. TLC"},{"key":"10.1016\/j.saa.2018.07.040_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/chromsci\/bms202","article-title":"Rapid quantitative determination of related substances and degradants in milnacipran","volume":"52","author":"Pydimarry","year":"2012","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.saa.2018.07.040_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4236\/ajac.2012.31007","article-title":"A stability indicating U-HPLC method for milnacipran in bulk drugs and pharmaceutical dosage forms","volume":"3","author":"Tondepu","year":"2012","journal-title":"Am. J. Anal. Chem."},{"key":"10.1016\/j.saa.2018.07.040_bb0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/rcm.6460","article-title":"Liquid chromatography\/electrospray ionization tandem mass spectrometric study of milnacipran and its stressed degradation products","volume":"27","author":"Borkar","year":"2013","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.saa.2018.07.040_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1573412911309020010","article-title":"Development and validation of a stability indicating liquid chromatographic method for the determination of milnacipran in bulk and its formulations","volume":"9","author":"Singhvi","year":"2013","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/j.saa.2018.07.040_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/10826076.2012.734002","article-title":"Quantitative determination of milnacipran Hcl in rabbit plasma by Hplc and its application to pharmacokinetics study","volume":"37","author":"Parejiya","year":"2014","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.saa.2018.07.040_bb0085","first-page":"604","article-title":"Stability-indicating MEKC method for determination of milnacipran in capsules","volume":"6","author":"Dias","year":"2014","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/j.saa.2018.07.040_bb0090","series-title":"Colorimetric and Fluorimetric Analysis of Organic Compounds and Drugs","author":"Pesez","year":"1974"},{"key":"10.1016\/j.saa.2018.07.040_bb0095","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.saa.2014.10.079","article-title":"Development of spectrofluorimetric method for determination of certain aminoglycoside drugs in dosage forms and human plasma through condensation with ninhydrin and phenyl acetaldehyde","volume":"136 (","author":"Omar","year":"2015","journal-title":"Spectrochim. Acta A"},{"key":"10.1016\/j.saa.2018.07.040_bb0100","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s10895-017-2066-6","article-title":"Selectivity improvement for Spectrofluorimetric determination of oseltamivir phosphate in human plasma and in the presence of its degradation product","volume":"27","author":"Omar","year":"2017","journal-title":"J. Fluoresc."},{"key":"10.1016\/j.saa.2018.07.040_bb0105","author":"ICH Harmonized Tripartie Guidline Q2A"}],"container-title":["Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386142518306942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386142518306942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T03:14:26Z","timestamp":1571627666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386142518306942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":21,"alternative-id":["S1386142518306942"],"URL":"https:\/\/doi.org\/10.1016\/j.saa.2018.07.040","relation":{},"ISSN":["1386-1425"],"issn-type":[{"value":"1386-1425","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An experimental ninhydrin design approach for the sensitive spectrofluorimetric assay of milnacipran in human urine and plasma","name":"articletitle","label":"Article Title"},{"value":"Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.saa.2018.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}